Alternative lengthening of telomeres in primary hepatic neoplasms

被引:4
|
作者
Yasir, Saba [1 ]
Thompson, Scott [2 ]
Chen, Zongming Eric [1 ]
Knudson, Ryan [3 ]
Knutson, Darlene [3 ]
Kloft-Nelson, Sara [3 ]
Graham, Rondell P. [1 ]
Jain, Dhanpat [4 ]
Simon, Sanford M. [5 ]
Wu, Tsung-Teh [1 ]
Torbenson, Michael [1 ]
机构
[1] Mayo Clin, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Radiol, Rochester, MN 55905 USA
[3] Mayo Clin, Cytogenet Core Lab, Med Genome Facil, Rochester, MN 55905 USA
[4] Dept Pathol, Yale, CT 06520 USA
[5] Rockefeller Univ, Lab Cellular Biophys, 1230 York Ave, New York, NY 10065 USA
关键词
Hepatocellular carci-noma; Fibrolamellar carcinoma; Angiosarcoma; Cholangiocarcinoma; Alternative lenthening of telomeres; Combined hepatocellular carcinoma-cholangio-carcinoma; Carcinosarcoma; CANCER; TUMORS; ATRX; CARCINOMA; PHENOTYPE; DAXX;
D O I
10.1016/j.humpath.2022.11.003
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The alternative lengthening of telomeres (ALT) phenotype is characterized by ultra-bright telomeres on fluorescence in situ hybridization (FISH) and is a marker of a unique mechanism of telo-mere maintenance in tumors. ALT does not occur in normal tissues. ALT has been described in hepa-tocellular carcinoma (5-10%) and in primary hepatic angiosarcomas (75%). To study the frequency of ALT in other primary hepatic tumors, a wide range of primary hepatic neoplasms were retrieved. The tumors included the following: intrahepatic and hilar cholangiocarcinomas (N = 110), hepatic ade-nomas (N = 35), hepatocellular carcinomas (N = 30), fibrolamellar carcinomas (n = 11), combined cholangiocarcinoma-hepatocellular carcinomas (N = 8), carcinosarcoma (N = 10), hepatoblastomas (N = 5), hemangiomas (N = 4), angiosarcomas (N = 8), epithelioid hemangioendotheliomas (N = 10), calcified nested stromal epithelial tumor (N = 2), embryonal sarcoma (N = 2), rhabdoid tumor (N = 1), bile duct adenoma (N = 1), and angiomyolipoma (N = 1). For epithelial tumors, ALT-FISH was positive in one carcinosarcoma (10% of cases), one cholangiocarcinoma (1% of cases), and one combined hepatocellular carcinoma-cholangiocarcinoma (13% of cases). In the hepatocellular carcinoma component of both the carcinosarcoma and the combined hepatocellular carcinoma-cholangiocarcinoma, the tumor cells showed patchy marked nuclear pleomorphism akin to that described previously for chromophobe hepatocellular carcinoma, which are typically ALT FISH pos-itive. The ALT-positive cholangiocarcinoma also showed patchy, striking nuclear pleomorphism. For soft tissue tumors, ALT was positive in two angiosarcomas (N = 2; 25% of cases). In summary, this study shows that ALT-FISH is positive in rare carcinosarcomas, cholangiocarcinomas, and combined cholangiocarcinoma-hepatocellular carcinoma. ALT is not a significant mechanism of telomere main-tenance in hepatocellular adenomas or fibrolamellar carcinomas and was negative in all other tested primary hepatic neoplasms. ALT-FISH is also positive in a subset of primary hepatic angiosarcomas.(c) 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:79 / 86
页数:8
相关论文
共 50 条
  • [31] Alternative Lengthening of Telomeres Is Rare in Canine Histiocytic Sarcoma
    Kreilmeier-Berger, Theresa
    Aupperle-Lellbach, Heike
    Reifinger, Martin
    Hoerstke, Nicolai Valentin
    Holzmann, Klaus
    Kleiter, Miriam
    CANCERS, 2023, 15 (17)
  • [32] Alternative Lengthening of Telomeres in Pediatric Cancer: Mechanisms to Therapies
    Kent, Thomas
    Gracias, Deanne
    Shepherd, Samuel
    Clynes, David
    FRONTIERS IN ONCOLOGY, 2020, 9
  • [33] Detection of alternative lengthening of telomeres mechanism on tumor sections
    Claude, Eloise
    de Lhoneux, Guillaume
    Pierreux, Christophe E.
    Marbaix, Etienne
    de Goyet, Maelle de Ville
    Boulanger, Cecile
    Van Damme, An
    Brichard, Benedicte
    Decottignies, Anabelle
    MOLECULAR BIOMEDICINE, 2021, 2 (01):
  • [34] Alternative lengthening of telomeres in cancer stem cells in vivo
    B Bojovic
    R E Booth
    Y Jin
    X Zhou
    D L Crowe
    Oncogene, 2015, 34 : 611 - 620
  • [35] Alternative lengthening of telomeres in cancer stem cells in vivo
    Bojovic, B.
    Booth, R. E.
    Jin, Y.
    Zhou, X.
    Crowe, D. L.
    ONCOGENE, 2015, 34 (05) : 611 - 620
  • [36] Alternative lengthening of telomeres is not synonymous with mutations in ATRX/DAXX
    Alexandre de Nonneville
    Roger R. Reddel
    Nature Communications, 12
  • [37] Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme
    Hakin-Smith, V
    Jellinek, DA
    Levy, D
    Carroll, T
    Teo, M
    Timperley, WR
    McKay, MJ
    Reddel, RR
    Royds, JA
    LANCET, 2003, 361 (9360): : 836 - 838
  • [38] Reintroduction of DAXX suppresses alternative lengthening of telomeres in osteosarcoma
    Driest, Kathryn E.
    Waterfall, Joshua J.
    Walker, Robert L.
    Pineda, Marbin A.
    Abaan, Ogan
    Zhu, Yuelin J.
    Wang, Yonghong
    Ester, Corbin D.
    Davis, Sean R.
    Bilke, Sven
    Meltzer, Paul S.
    CANCER RESEARCH, 2016, 76
  • [39] G-quadruplexes mark alternative lengthening of telomeres
    Yang, Sunny Y.
    Chang, Emily Y. C.
    Lim, Joanne
    Kwan, Harwood H.
    Monchaud, David
    Yip, Stephen
    Stirling, Peter C.
    Wong, Judy M. Y.
    NAR CANCER, 2021, 3 (03):
  • [40] Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas
    Scheel, C
    Schaefer, KL
    Jauch, A
    Keller, M
    Wai, D
    Brinkschmidt, C
    van Valen, F
    Boecker, W
    Dockhorn-Dworniczak, B
    Poremba, C
    ONCOGENE, 2001, 20 (29) : 3835 - 3844